Metoprolol tartrate has been evaluated in numerous clinical trials spanning Phase I through post-marketing Phase IV studies. These protocols assess the drug across cardiovascular indications—including heart failure, hypertension, and atrial fibrillation—as well as viral infections and drug-drug interactions. Sponsored by global pharmaceutical companies and academic research institutions, the overall portfolio includes completed, actively recruiting, and terminated or withdrawn trials.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06964464 | RECRUITING | Heart Failure With Reduced Ejection Fraction (HFrEF); Sudden Cardiac Death; Ventricular Arrhythmia; Implantable Cardioverter Defibrillator (ICD); Beta-blocker Therapy; Cardiomyopathy |
University of Rochester |
2025-08-17 | PHASE4 |
| NCT07519161 | NOT_YET_RECRUITING | Atrial Fibrillation |
Shanghai East Hospital |
2026-04-07 | |
| NCT07490067 | RECRUITING | Heart Failure With Reduced Ejection Fraction |
University of Michigan |
2026-10 | PHASE4 |
| NCT07445789 | NOT_YET_RECRUITING | Atrial Fibrillation (AF) |
Martini Hospital Groningen |
2026-06 | PHASE4 |
| NCT07632157 | NOT_YET_RECRUITING | Atrial Flutter With Rapid Ventricular Response |
Wake Forest University Health Sciences |
2026-10 | PHASE3 |
| NCT07755904 | NOT_YET_RECRUITING | Cardiomyopathy, Hypertrophic Obstructive |
Braveheart Bio, Inc. |
2026-10 | PHASE3 |
| NCT07268170 | ENROLLING_BY_INVITATION | Coronary Arterial Disease (CAD); Ischemic Heart Disease (IHD) |
Gødstrup Hospital |
2025-12-15 | PHASE2; PHASE3 |
| NCT07568574 | ENROLLING_BY_INVITATION | Safety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite Athletes |
Enhanced Emirates Limited |
2026-03-12 | |
| NCT06825728 | NOT_YET_RECRUITING | Heart Failure With Reduced Ejection Fraction (HFrEF); COPD (Chronic Obstructive Pulmonary Disease) |
Xiangya Hospital of Central South University |
2025-02 | PHASE4 |
| NCT07706075 | NOT_YET_RECRUITING | Atrial Fibrillation (AF); Atrial Fibrillation With Rapid Ventricular Response |
Muhammad Ali Javed |
2027-01-01 | PHASE4 |
| NCT07597564 | NOT_YET_RECRUITING | General Anesthesia; Tracheal Intubation |
Fujian Provincial Hospital |
2026-06-22 | PHASE4 |
| NCT06967194 | RECRUITING | ST Segment Elevation Myocardial Infarction (STEMI); Cardiogenic Shock Post Myocardial Infarction |
Tel-Aviv Sourasky Medical Center |
2025-05-21 | |
| NCT05931276 | RECRUITING | End-Stage Kidney Disease; End-Stage Renal Disease |
VA Office of Research and Development |
2024-05-22 | PHASE3 |
| NCT06569212 | RECRUITING | Non-Traumatic Subarachnoid Hemorrhage |
Madeleine Puissant |
2024-09-23 | PHASE4 |
| NCT07103655 | NOT_YET_RECRUITING | Hypertrophic Cardiomyopathy (HCM) |
Second Affiliated Hospital, Zhejiang University, School of Medicine |
2026-01-01 | PHASE4 |
| NCT05631730 | RECRUITING | Mitral Valve Prolapse; Ventricular Arrhythmias and Cardiac Arrest |
Oslo University Hospital |
2023-01-04 | PHASE3 |
| NCT06035978 | UNKNOWN | Cardiovascular Diseases; Heart Failure With Reduced Ejection Fraction |
University Hospital Ostrava |
2024-03 | PHASE4 |
| NCT04914234 | RECRUITING | Hypotension Drug-Induced |
Damanhour Teaching Hospital |
2025-08-01 | PHASE4 |
| NCT06879769 | RECRUITING | Coronary Computed Tomography Angiography; Contrast Media; Cardiac Output |
Karolinska University Hospital |
2021-01-01 | |
| NCT06864234 | RECRUITING | Coronary Arterial Disease (CAD); Angina (Stable); Microvascular Circulation |
VZW Cardiovascular Research Center Aalst |
2025-07-03 | PHASE4 |
| NCT03566667 | COMPLETED | Chronic Obstructive Pulmonary Disease |
Ole Frobert, MD, PhD |
2018-06-12 | PHASE4 |
| NCT06686628 | COMPLETED | Dermatitis Atopic |
Sanofi |
2024-11-20 | PHASE1 |
| NCT05847517 | TERMINATED | Acute Respiratory Distress Syndrome (ARDS) |
Consorcio Centro de Investigación Biomédica en Red (CIBER) |
2024-07-10 | PHASE3 |
| NCT01608893 | UNKNOWN | Atrial Fibrillation |
University of Calgary |
2012-05 | |
| NCT06808802 | COMPLETED | Healthy |
Eli Lilly and Company |
2025-02-03 | PHASE1 |
| NCT03778554 | ACTIVE_NOT_RECRUITING | Acute Myocardial Infarction; Non-ST Elevation Myocardial Infarction (nSTEMI); ST Elevation Myocardial Infarction |
Bispebjerg Hospital |
2018-12-17 | PHASE4 |
| NCT05546320 | COMPLETED | Patent Foramen Ovale; Migraine |
Chinese Academy of Medical Sciences, Fuwai Hospital |
2022-10-15 | PHASE2 |
| NCT05767346 | COMPLETED | Obstructive Hypertrophic Cardiomyopathy (oHCM) |
Cytokinetics |
2023-06-20 | PHASE3 |
| NCT04434664 | COMPLETED | Heart Failure With Preserved Ejection Fraction; Hypertension |
University of Pennsylvania |
2021-12-01 | PHASE4 |
| NCT07568873 | COMPLETED | Stress Response of Endotracheal Intubation and Surgical Field Clarity in FESS |
Zagazig University |
2024-01-25 | |
| NCT05891119 | COMPLETED | Atopic Dermatitis |
Amgen |
2023-06-03 | EARLY_PHASE1 |
| NCT05741385 | COMPLETED | Liver Cirrhosis |
Boehringer Ingelheim |
2023-10-10 | |
| NCT07378228 | COMPLETED | Coronary Heart Disease; Stable Angina Pectoris |
Xikun Li |
2023-07-01 | |
| NCT06357104 | COMPLETED | COVID-19 Vaccine Adverse Reaction |
Pachankis, Yang I., M.D. |
2024-02-26 | PHASE4 |
| NCT05745337 | UNKNOWN | Atrial Fibrillation; Diastolic Dysfunction; HFpEF - Heart Failure With Preserved Ejection Fraction |
University of Vermont |
2023-02-06 | PHASE1 |
| NCT03070184 | COMPLETED | Healthy; Pre Hypertension |
University of Alabama at Birmingham |
2017-04-30 | PHASE2 |
| NCT06592547 | COMPLETED | Septic Shock; Ventilator Acquired Pneumonia |
Alexandria University |
2022-04-01 | PHASE2 |
| NCT03278509 | UNKNOWN | Acute Myocardial Infarction; Non-ST Elevation Myocardial Infarction; ST Elevation Myocardial Infarction |
Karolinska Institutet |
2017-09-11 | PHASE4 |
| NCT05096884 | TERMINATED | Tachycardia; Dyspnea; COVID-19 |
Hackensack Meridian Health |
2022-03-23 | EARLY_PHASE1 |
| NCT05066633 | UNKNOWN | Muscular Dystrophy, Duchenne |
Medical University of Gdansk |
2021-08-18 | PHASE3 |
| NCT03138603 | COMPLETED | Heart Diseases |
University of Chicago |
2016-12 | PHASE3 |
| NCT06004453 | Recruiting | Heart Failure |
Novartis Pharmaceuticals|Novartis |
2023-04-04 | -- |
| NCT04661709 | UNKNOWN | Coronary Heart Disease; Unstable Angina; Chinese Herbal Medicine |
Guang'anmen Hospital of China Academy of Chinese Medical Sciences |
2021-03-01 | PHASE4 |
| NCT04133532 | COMPLETED | Hypertrophic Cardiomyopathy |
University Hospital, Motol |
2020-03-05 | PHASE4 |
| NCT03689946 | COMPLETED | Cardiovascular Disease; Hyperlipidemia |
Cedars-Sinai Medical Center |
2019-03-19 | PHASE3 |
| NCT05711810 | COMPLETED | Severe Acute Respiratory Syndrome-related Coronavirus; Renal Dialysis; Vaccines; Myocarditis Allergic; Infection Viral |
Yang I. Pachankis |
2023-01-02 | PHASE4 |
| NCT04082910 | UNKNOWN | Solid Tumor; Hematological Malignancy |
Chinese PLA General Hospital |
2019-09-15 | PHASE1; PHASE2 |
| NCT03943927 | COMPLETED | Post-operative Atrial Fibrillation |
Vanderbilt University Medical Center |
2021-03-05 | |
| NCT04457323 | UNKNOWN | Hypertension |
Neutec Ar-Ge San ve Tic A.Ş |
2022-01-15 | PHASE4 |
| NCT05368376 | COMPLETED | Hypotension Drug-Induced |
Damanhour Teaching Hospital |
2021-04-01 | PHASE4 |
| NCT07074834 | COMPLETED | Coronary Heart Disease (CHD) |
Shiyan City Renmin Hospital |
2021-02-01 | |
| NCT05368831 | COMPLETED | Healthy Volunteers |
NorthSea Therapeutics B.V. |
2022-07-19 | PHASE1 |
| NCT04049786 | UNKNOWN | Obesity; Bariatric Surgery; Roux-en Y Gastric Bypass |
Natalia Valadares de Moraes |
2019-06-01 | PHASE4 |
| NCT05368831 | Completed | Healthy Volunteers |
NorthSea Therapeutics B.V. |
2022-07-19 | Phase 1 |
| NCT04513509 | COMPLETED | Atrial Fibrillation; Rate Control; Cardiopulmonary Exercise Test |
National Taiwan University Hospital |
2020-10-21 | |
| NCT05261464 | UNKNOWN | Heart Rate; Coronary Computed Tomography Angiography |
Mahidol University |
2021-01-30 | PHASE4 |
| NCT04504045 | TERMINATED | Diabetes Mellitus, Type 2 |
University of Southern Denmark |
2020-09-01 | PHASE1 |
| NCT05768542 | COMPLETED | Takotsubo Cardiomyopathy |
Danderyd Hospital |
2016-04-12 | PHASE1; PHASE2 |
| NCT03008382 | COMPLETED | Interstitial Cystitis/Painful Bladder Syndrome; Myofascial Pelvic Pain |
Virginia Commonwealth University |
2017-03-01 | PHASE4 |
| NCT05171985 | Unknown status | COVID-19 Pneumonia|Atrial Fibrillation |
Tanta University |
2022-01 | Not Applicable |
| NCT02695992 | COMPLETED | Atrial Fibrillation; Permanent Atrial Fibrillation |
Asker & Baerum Hospital |
2016-02 | PHASE4 |
| NCT04842981 | Terminated | Arthritis Rheumatoid|Interaction |
University of Southern Denmark|Odense University Hospital|Hospital of South West Jutland|King Christian X´Hospital for Rheumatic Diseases|Sygehus Lillebaelt|Odense Patient Data Explorative Network |
2021-05-25 | Phase 1|Phase 2 |
| NCT04713254 | COMPLETED | Healthy |
H. Lundbeck A/S |
2020-12-08 | PHASE1 |
| NCT04425902 | COMPLETED | HIV Infections |
ViiV Healthcare |
2020-12-16 | PHASE1 |
| NCT02123056 | UNKNOWN | Vasovagal Syncope |
University of Calgary |
2014-10 | PHASE4 |
| NCT03082352 | UNKNOWN | Healthy |
Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited |
2020-08 | PHASE1 |
| NCT03845075 | COMPLETED | Hypothalamic Injury-induced Obesity (HIO) |
Saniona |
2019-02-25 | PHASE2 |
| NCT03532802 | COMPLETED | Hypertrophic Cardiomyopathy |
Steen Hvitfeldt Poulsen |
2018-05-01 | PHASE2 |
| NCT03579914 | COMPLETED | Anterior Myocardial Infarction; Heart Failure |
Harbin Medical University |
2017-11-28 | |
| NCT03556592 | COMPLETED | Atopic Dermatitis |
LEO Pharma |
2018-08-13 | PHASE1 |
| NCT03696758 | COMPLETED | Infant,Premature |
University of Wisconsin, Madison |
2018-10-30 | PHASE2 |
| NCT03830957 | UNKNOWN | Heart Failure; CT Angiography; Ischemic Cardiomyopathy; Non-ischemic Cardiomyopathy; Heart Failure, Systolic; Heart Failure,Congestive; Heart Failure, Diastolic; Heart Rate Low |
Rajaie Cardiovascular Medical and Research Center |
2018-11-26 | |
| NCT02587351 | TERMINATED | Pulmonary Disease, Chronic Obstructive |
University of Minnesota |
2016-05-01 | PHASE3 |
| NCT03413410 | UNKNOWN | ACS - Acute Coronary Syndrome |
Yun Dai Chen |
2018-02-01 | |
| NCT03149445 | COMPLETED | Confirmed Genetic Diagnosis of Prader-Willi Syndrome |
Saniona |
2017-03-30 | PHASE2 |
| NCT03488719 | COMPLETED | Phase 1 |
Saniona |
2018-07-11 | PHASE1 |
| NCT03384524 | WITHDRAWN | Diabetic Macular Edema |
Andrew Moshfeghi, MD, MBA |
2018-03 | PHASE1; PHASE2 |
| NCT03162120 | WITHDRAWN | Atrial Fibrillation; Recurrence |
Elpen Pharmaceutical Co. Inc. |
2018-09-01 | PHASE2; PHASE3 |
| NCT02025465 | UNKNOWN | Atrial Fibrillation; Atrial Flutter |
CAMC Health System |
2013-12 | PHASE4 |
| NCT03072121 | UNKNOWN | Coronary Artery Disease(CAD) |
Jun Li |
2017-06 | PHASE4 |
| NCT03072082 | UNKNOWN | Coronary Artery Disease(CAD) |
Jun Li |
2017-06 | PHASE4 |
| NCT02248753 | COMPLETED | Atrial Fibrillation |
Maastricht University Medical Center |
2014-10 | |
| NCT02612298 | COMPLETED | Essential Hypertension |
Marubeni Pharmaceuticals (Suzhou) Co., Ltd. |
2015-08 | PHASE4 |
| NCT02417246 | COMPLETED | Blood Pressure |
University of Florida |
2015-08 | PHASE4 |
| NCT03457597 | COMPLETED | Healthy |
Corcept Therapeutics |
2018-03-06 | PHASE1 |
| NCT01837069 | TERMINATED | Osteoarthritis; Cardiovascular Disease |
NYU Langone Health |
2014-02 | PHASE4 |
| NCT03441412 | COMPLETED | Healthy Volunteers |
Vastra Gotaland Region |
2018-02-28 | PHASE1 |
| NCT02269696 | WITHDRAWN | Breast Cancer |
Kuopio University Hospital |
2018-03-21 | PHASE3 |
| NCT03286829 | COMPLETED | Healthy Male Subjects |
Saniona |
2017-12-18 | PHASE1 |
| NCT01970501 | COMPLETED | Current or Recent History of Atrial Fibrillation |
ARCA Biopharma, Inc. |
2014-04 | PHASE2 |
| NCT02513927 | UNKNOWN | Hypertension |
First Affiliated Hospital of Harbin Medical University |
2015-08 | PHASE2; PHASE3 |
| NCT01595516 | COMPLETED | Prehypertension; Hypertension |
University of Colorado, Boulder |
2012-02 | PHASE4 |
| NCT02251509 | UNKNOWN | Atrial Fibrillation |
Creighton University |
2016-12 | PHASE4 |
| NCT02772354 | UNKNOWN | Ventricular Arrhythmia |
Meshalkin Research Institute of Pathology of Circulation |
2016-04 | PHASE2; PHASE3 |
| NCT02293096 | TERMINATED | Hypertension |
University of Colorado, Denver |
2014-09 | |
| NCT02772601 | COMPLETED | Psoriasis |
AbbVie |
2016-09-15 | PHASE1 |
| NCT03103568 | COMPLETED | Drug Drug Interaction |
Swedish Orphan Biovitrum |
2017-03-28 | PHASE1 |
| NCT02408172 | UNKNOWN | Sleep Apnea Syndrome; Hypertension |
First Affiliated Hospital of Harbin Medical University |
2013-10 | PHASE2; PHASE3 |
| NCT02924454 | COMPLETED | Drug Overdose; Overdose of Beta-adrenergic Blocking Drug; Blood Pressure |
Mikkel Bring Christensen |
2016-09 | PHASE4 |
| NCT02737891 | COMPLETED | Type 2 Diabetes Mellitus |
Saniona |
2016-04 | PHASE2 |
| NCT00223717 | COMPLETED | Hypertension |
Vanderbilt University |
2001-01 | PHASE1 |
| NCT02809820 | COMPLETED | Acute Coronary Syndrome |
Federico II University |
2016-05 | PHASE4 |
| NCT02940379 | COMPLETED | Type 2 Diabetes Mellitus |
Sanofi |
2016-10 | PHASE1 |
| NCT01395329 | COMPLETED | Prehypertension; Hypertension |
University of Colorado, Boulder |
2011-05 | PHASE4 |
| NCT02746575 | COMPLETED | Adrenergic Beta-Receptor Blockader; Troponin Levels; Cardiomyopathy, Post-surgical |
Washington University School of Medicine |
2015-11 | PHASE4 |
| NCT02361619 | COMPLETED | Healthy Volunteers |
Turku University Hospital |
2015-02 | PHASE1 |
| NCT02647086 | COMPLETED | Atopic Dermatitis |
Regeneron Pharmaceuticals |
2015-12 | PHASE1 |
| NCT01458600 | COMPLETED | Graves´ Disease |
Mikael Lantz |
2006-09 | PHASE4 |
| NCT02578277 | COMPLETED | HIV Infections |
ViiV Healthcare |
2015-11-09 | PHASE1 |
| NCT01728272 | UNKNOWN | Drug Absorption |
Kuopio University Hospital |
2012-11 | |
| NCT02484859 | COMPLETED | Nasal Polyps |
Recep Tayyip Erdogan University |
2015-07 | PHASE4 |
| NCT01501929 | COMPLETED | Hypertension |
University of Texas Southwestern Medical Center |
2010-08 | PHASE4 |
| NCT00756236 | COMPLETED | Myocardial Ischemia |
University of Oklahoma |
2008-10 | |
| NCT05008250 | COMPLETED | Premature Ventricular Contraction |
Xuanwu Hospital, Beijing |
2014-01 | PHASE4 |
| NCT01901549 | UNKNOWN | Acute Coronary Syndrome; Arterial Hypertension |
Meshalkin Research Institute of Pathology of Circulation |
2013-06 | PHASE2 |
| NCT02029118 | COMPLETED | Stable Angina Pectoris |
Chengdu University of Traditional Chinese Medicine |
2012-10 | EARLY_PHASE1 |
| NCT02012075 | UNKNOWN | Heart Failure |
Jiangsu HengRui Medicine Co., Ltd. |
2013-12 | PHASE3 |
| NCT01755663 | UNKNOWN | Coronary Artery Disease |
Col. Suthee Panichkul |
2014-12 | PHASE4 |
| NCT02254148 | COMPLETED | Healthy |
Boehringer Ingelheim |
2014-10 | PHASE1 |
| NCT01434134 | COMPLETED | Breast Cancer; Heart Failure |
University Hospital, Akershus |
2011-09 | PHASE2 |
| NCT01157572 | COMPLETED | Aortic Valve Insufficiency |
Oslo University Hospital |
2010-08 | PHASE4 |
| NCT01157234 | COMPLETED | Hypertension |
University of Florida |
2010-07 | PHASE4 |
| NCT01658657 | COMPLETED | Hypertension; Plasma Renin Activity |
University of North Carolina, Chapel Hill |
2012-10 | |
| NCT01044693 | COMPLETED | Hypertension; Pure Autonomic Failure; Multiple System Atrophy |
Vanderbilt University |
2010-01 | |
| NCT01499134 | COMPLETED | Peripheral Artery Disease; Hypertension |
Thomas Jefferson University |
2011-08 | PHASE3 |
| NCT02045966 | COMPLETED | Hepatitis C |
Bristol-Myers Squibb |
2014-02 | PHASE1 |
| NCT01203852 | COMPLETED | Hypertension |
University of Florida |
2010-08 | PHASE4 |
| NCT01508325 | COMPLETED | Hypertension |
Merck KGaA, Darmstadt, Germany |
2011-12 | PHASE4 |
| NCT02097511 | COMPLETED | Hypertension; Peripheral Artery Disease |
Ajou University School of Medicine |
2013-12 | PHASE1 |
| NCT01041287 | COMPLETED | Hypertension |
Emory University |
2009-12 | PHASE4 |
| NCT01845194 | COMPLETED | Drug Biotransformation; Membrane Transport |
Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH |
2009-12 | PHASE1 |
| NCT01902550 | WITHDRAWN | Healthy |
Janssen Research & Development, LLC |
2013-07 | PHASE1 |
| NCT01970059 | UNKNOWN | Hypertension |
Jiangsu HengRui Medicine Co., Ltd. |
2013-10 | PHASE3 |
| NCT01676285 | COMPLETED | Cirrhosis; Cirrhotic Cardiomyopathy; Cardiac Remodeling |
University of Sao Paulo |
2012-01 | PHASE3 |
| NCT01441570 | TERMINATED | Transplant; Failure, Kidney; Hypertension |
Brigham and Women's Hospital |
2012-02 | |
| NCT01917149 | COMPLETED | Dilated Cardiomyopathy |
Xijing Hospital |
2005-03 | PHASE4 |
| NCT01884857 | COMPLETED | Fasting |
IPCA Laboratories Ltd. |
2013-04 | PHASE1 |
| NCT01502787 | COMPLETED | Hypertension |
University of Texas Southwestern Medical Center |
2009-04 | PHASE4 |
| NCT01281787 | COMPLETED | Lung Cancer; Atrial Fibrillation |
European Institute of Oncology |
2008-04 | PHASE3 |
| NCT01884909 | COMPLETED | Fed |
IPCA Laboratories Ltd. |
2013-04 | PHASE1 |
| NCT00995072 | COMPLETED | Hypertension; Female Sexual Dysfunction |
East Coast Institute for Research |
2009-10 | |
| NCT01884896 | COMPLETED | Fasting |
IPCA Laboratories Ltd. |
2013-02 | PHASE1 |
| NCT01605370 | TERMINATED | Hypertension |
Mayo Clinic |
2012-06 | PHASE4 |
| NCT01585623 | COMPLETED | Solid Tumor |
Bristol-Myers Squibb |
2012-06 | PHASE1 |
| NCT03882710 | COMPLETED | Diastolic Heart Failure |
Post Graduate Institute of Medical Education and Research, Chandigarh |
2010-01 | PHASE2 |
| NCT01311700 | COMPLETED | Myocardial Infarction |
Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III |
2010-11 | PHASE4 |
| NCT01523002 | COMPLETED | Malaria |
Medicines for Malaria Venture |
2012-01 | PHASE1 |
| NCT01659944 | COMPLETED | Healthy |
Genzyme, a Sanofi Company |
2012-05 | PHASE1 |
| NCT00806390 | TERMINATED | Cardiomyopathy |
University of Maryland, Baltimore |
2008-07 | PHASE4 |
| NCT01049009 | COMPLETED | High Blood Pressure |
Emory University |
2009-12 | PHASE4 |
| NCT01863173 | COMPLETED | B Thalassemia |
Shiraz University of Medical Sciences |
2012-01 | PHASE2; PHASE3 |
| NCT00829296 | COMPLETED | Hypertension; Diabetes |
University of Chicago |
2009-01 | PHASE2; PHASE3 |
| NCT01330654 | WITHDRAWN | Cardiac Event Risk |
University of California, San Francisco |
2011-03 | |
| NCT00992056 | COMPLETED | Hypertension |
University of Miami |
2010-12 | PHASE4 |
| NCT00585871 | WITHDRAWN | Ventricular Tachycardia |
James Martins |
2006-05 | |
| NCT00605072 | COMPLETED | Cognitive Impairment; Hypertension; Aging |
University of Southern California |
2008-01 | PHASE2 |
| NCT01029223 | WITHDRAWN | Blood Pressure |
Bayside Health |
2008-10 | PHASE4 |
| NCT01655303 | COMPLETED | Rapid Ventricular Response Atrial Fibrillation |
Tehran University of Medical Sciences |
2011-02 | PHASE4 |
| NCT00825123 | TERMINATED | Central Arterial Pressure |
Bayside Health |
2008-10 | PHASE4 |
| NCT01337674 | COMPLETED | Hypertension |
Merck Sharp & Dohme LLC |
2011-04-01 | PHASE1 |
| NCT01213173 | COMPLETED | Angina Pectoris |
AstraZeneca |
2010-10 | PHASE4 |
| NCT01324388 | COMPLETED | Diabetes Mellitus, Type 2 |
Eli Lilly and Company |
2011-03 | PHASE1 |
| NCT00401882 | TERMINATED | Cardiac Arrest; Sudden Cardiac Death; Ventricular Fibrillation; Tachycardia, Ventricular |
David Haines, MD |
2007-01 | PHASE2 |
| NCT00775671 | COMPLETED | Metabolic Syndrome |
Vanderbilt University |
2008-10 | PHASE4 |
| NCT03635125 | COMPLETED | JNC 7 Stage 1 or 2 Hypertension |
Trinity Hypertension & Metabolic Research Institute |
2010-08-30 | PHASE4 |
| NCT01404767 | TERMINATED | Vascular Disease; Hypertension; Angina; Cardiac Disease |
University Health Network, Toronto |
2011-04 | PHASE4 |
| NCT01187862 | COMPLETED | Cytochrome; Pharmacokinetics |
University Hospital, Basel, Switzerland |
2010-07 | PHASE1 |
| NCT01694797 | COMPLETED | Healthy |
Dr. Reddy's Laboratories Limited |
2011-01 | PHASE1 |
| NCT00999102 | COMPLETED | Hypertension |
Weill Medical College of Cornell University |
2009-10 | PHASE4 |
| NCT01673997 | COMPLETED | Healthy |
Dr. Reddy's Laboratories Limited |
2010-12 | PHASE1 |
| NCT01914926 | COMPLETED | Heart Rate and Rhythm Disorders |
Antonios Likourezos |
2009-06 | PHASE4 |
| NCT00849810 | TERMINATED | Hypertension |
University of Mississippi Medical Center |
2009-01 | |
| NCT01211821 | COMPLETED | Atrial Fibrillation |
Bristol-Myers Squibb |
2010-09 | PHASE1 |
| NCT00865917 | UNKNOWN | Postural Orthostatic Tachycardia Syndrome |
Hannover Medical School |
2008-11 | PHASE2 |
| NCT01238705 | UNKNOWN | Hypertension; Sexual Dysfunction |
LanZhou University |
2008-04 | PHASE4 |
| NCT00313157 | COMPLETED | Atrial Fibrillation |
Asker & Baerum Hospital |
2006-04 | PHASE3 |
| NCT01052428 | COMPLETED | Mitral Regurgitation |
University of Alabama at Birmingham |
2004-08 | PHASE2; PHASE3 |
| NCT00744237 | COMPLETED | Hypertension; Type 2 Diabetes Mellitus |
Forest Laboratories |
2008-08 | PHASE4 |
| NCT00993421 | TERMINATED | Obesity |
Eli Lilly and Company |
2009-10 | PHASE2 |
| NCT00627861 | TERMINATED | Hypertension |
The Rogosin Institute |
2008-11 | |
| NCT01051947 | WITHDRAWN | Central Aortic Pressure |
Creighton University |
2009-12 | |
| NCT00563238 | WITHDRAWN | Myocardial Ischemia |
Gregory A. Schmidt |
2007-11 | |
| NCT00783900 | COMPLETED | Atrial Fibrillation; Biatrial Pacing; Metoprolol |
Kuopio University Hospital |
2007-01 | PHASE4 |
| NCT00885651 | UNKNOWN | Heart Failure |
Rigshospitalet, Denmark |
2008-09 | PHASE4 |
| NCT00661895 | COMPLETED | Hypertension |
Creighton University |
2005-08 | PHASE4 |
| NCT00648895 | COMPLETED | Hypertension |
Forest Laboratories |
2007-11 | PHASE3 |
| NCT00292162 | COMPLETED | Chronic Heart Failure; Atrial Fibrillation |
NHS Greater Glasgow and Clyde |
2007-01 | |
| NCT00784316 | COMPLETED | Atrial Fibrillation; Cardiac Surgery |
Kuopio University Hospital |
2007-08 | PHASE4 |
| NCT00433043 | TERMINATED | Congestive Heart Failure |
St. Luke's-Roosevelt Hospital Center |
2007-01 | PHASE4 |
| NCT01798992 | COMPLETED | Idiopathic Dilated Cardiomyopathy |
University of Colorado, Denver |
2000-09 | PHASE4 |
| NCT00391846 | COMPLETED | Heart Failure; Ventricular Dysfunction, Left |
AstraZeneca |
2006-10 | PHASE4 |
| NCT00491387 | TERMINATED | Hypertension |
University of Cincinnati |
2007-08 | PHASE4 |
| NCT01248338 | COMPLETED | Hypertension |
Berlin-Chemie AG Menarini Group |
2006-03 | PHASE4 |
| NCT00732511 | UNKNOWN | Endothelial Function; Diabetes Mellitus; Hypertension |
State University of New York - Downstate Medical Center |
2008-04 | PHASE4 |
| NCT00942487 | COMPLETED | Primary Arterial Hypertension |
Berlin-Chemie Menarini |
2005-04 | PHASE3 |
| NCT03370835 | COMPLETED | Pulmonary Disease, Chronic Obstructive; Asthma; Adverse Effect of Beta-adrenoreceptor Antagonists |
VA Greater Los Angeles Healthcare System |
2004-06 | PHASE4 |
| NCT00642434 | COMPLETED | Diabetes |
University of New Mexico |
2004-01 | PHASE4 |
| NCT00384566 | WITHDRAWN | Heart Failure; Chronic Obstructive Airway Disease |
The Alfred |
2005-06 | PHASE4 |
| NCT00142584 | COMPLETED | Hypertension |
Mylan Bertek Pharmaceuticals |
2005-08 | PHASE3 |
| NCT00547300 | TERMINATED | Hypertension |
Forest Laboratories |
2007-10-31 | PHASE3 |
| NCT00273052 | COMPLETED | Hypertension |
GlaxoSmithKline |
2006-01-05 | PHASE3 |
| NCT00226096 | COMPLETED | CVA (Cerebrovascular Accident); Cerebral Hemorrhage; Intracranial Hemorrhages |
The George Institute |
2005-11 | |
| NCT00166400 | COMPLETED | Heart Valve Diseases |
Mayo Clinic |
2004-07 | PHASE4 |
| NCT00182039 | TERMINATED | Cardiovascular Diseases |
Hamilton Health Sciences Corporation |
2002-10 | PHASE3 |
| NCT02336607 | COMPLETED | Hypertension |
AstraZeneca |
2005-12 | |
| NCT00123604 | COMPLETED | Hypertension; Type 2 Diabetes Mellitus |
St. Paul Heart Clinic |
2004-06 | PHASE4 |
| NCT00123903 | TERMINATED | Heart Failure, Congestive and Microalbuminuria |
GlaxoSmithKline |
2005-07 | PHASE3 |
| NCT00861016 | COMPLETED | Hypertension |
AstraZeneca |
2005-10 | PHASE4 |
| NCT00152633 | WITHDRAWN | Hypertension |
University of Erlangen-Nürnberg Medical School |
2005-09 | PHASE2; PHASE3 |
| NCT00077948 | TERMINATED | Heart Failure, Congestive |
Gilead Sciences |
2003-07 | PHASE3 |
| NCT00802230 | COMPLETED | Heart Failure |
University of Utah |
2002-09 | PHASE4 |
| NCT02242812 | TERMINATED | Hypertension |
Boehringer Ingelheim |
2003-09 | PHASE4 |
| NCT00642096 | COMPLETED | High Blood Pressure (Hypertension). |
AstraZeneca |
2003-06 | PHASE3 |
| NCT00060918 | COMPLETED | Hypertension |
GlaxoSmithKline |
2001-06 | PHASE4 |
| NCT00060931 | COMPLETED | Hypertension |
GlaxoSmithKline |
2001-06 | PHASE4 |
| NCT00679653 | COMPLETED | Obesity; Hypertension |
Abbott |
2002-02 | PHASE3 |
| NCT02264002 | COMPLETED | Healthy |
Boehringer Ingelheim |
2003-02 | PHASE1 |
| NCT00649688 | COMPLETED | Healthy |
Mylan Pharmaceuticals Inc |
2003-01 | PHASE1 |
| NCT00649233 | COMPLETED | Healthy |
Mylan Pharmaceuticals Inc |
2003-01 | PHASE1 |
| NCT00648271 | COMPLETED | Healthy |
Mylan Pharmaceuticals Inc |
2002-12 | PHASE1 |
| NCT00649116 | COMPLETED | Healthy |
Mylan Pharmaceuticals Inc |
2002-12 | PHASE1 |
| NCT01478490 | COMPLETED | Pharmacokinetics of Mirabegron; Healthy Subjects |
Astellas Pharma Inc |
2002-09 | PHASE1 |
| NCT01523054 | COMPLETED | Acute Myocardial Infarction |
AstraZeneca |
2000-02 | PHASE1 |
| NCT04364139 | COMPLETED | Hypertensive Nephrosclerosis; Chronic Renal Insufficiency |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
1995-02-01 | PHASE3 |
| NCT00255502 | COMPLETED | Hypertension |
AstraZeneca |
2002-07 | PHASE3 |
| NCT00198614 | COMPLETED | Coronary Disease; Atrial Fibrillation |
Ministry of Health, Labour and Welfare, Japan |
2005-01 | |
| NCT00475462 | COMPLETED | Syncope, Vasovagal |
Peking University First Hospital |
2001-07 | |
| NCT00497003 | COMPLETED | Endothelial Function; Beta Blocker |
Bispebjerg Hospital |
2004-02 | PHASE4 |
| NCT00000499 | COMPLETED | Cardiovascular Diseases; Heart Diseases; Hypertension; Vascular Diseases |
National Heart, Lung, and Blood Institute (NHLBI) |
1980-09 | PHASE2 |
| NCT00819104 | COMPLETED | Primary Hypertension |
AstraZeneca |
2008-11 | PHASE4 |
| NCT00214318 | COMPLETED | Heart Failure |
University of Wisconsin, Madison |
2005-01 | |
| NCT00222573 | COMPLETED | Acute Myocardial Infarction |
University of Oxford |
1999-07 | PHASE4 |
| NCT00718406 | COMPLETED | Acute Coronary Syndromes |
Sahlgrenska University Hospital |
PHASE4 | |
| NCT00302692 | UNKNOWN | Multiple Trauma; Cardiovascular Diseases; Aged |
University of Texas Southwestern Medical Center |
2005-12 | PHASE2 |
| NCT00255528 | COMPLETED | Hypertension |
AstraZeneca |
2002-07 | PHASE3 |
| NCT00288548 | UNKNOWN | Chronic Obstructive Pulmonary Disease (COPD) |
Martini Hospital Groningen |
2006-02 | PHASE4 |
| NCT00930306 | COMPLETED | Chronic Pain |
AstraZeneca |
2009-06 | PHASE1 |
(data from https://clinicaltrials.gov, updated on 2025-09-18)
Check the
Metoprolol Tartrate
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
- Metoprolol Tartrate Solubility in DMSO
- Metoprolol Tartrate Stock Solution
- Metoprolol Tartrate Storage
- Metoprolol Tartrate Stability
- Metoprolol Tartrate Molecular Weight
- Metoprolol Tartrate SMILES
- Metoprolol Tartrate CAS Number
- Metoprolol Tartrate Chemical Structure (2D and 3D)
- Metoprolol Tartrate SDS|MSDS
Note: Technical data last updated: Sep 1, 2026.